Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIMIS: Safety and Efficacy of ACT017 in Acute Ischemic Stroke
NCT03803007Phase 2Completed
- Sponsor
- Acticor Biotech
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glenzocimab in ischemic stroke (5 arms), sponsored by Acticor Biotech. Primary endpoints: Symptomatic Intracranial Haemorrhages at 24 hours and Incidence of Non-Symptomatic Intracranial Haemorrhages at 24 hours. Started Mar 2019; status: completed.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03803007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803007.